scholarly journals Anticoronavirus and Immunomodulatory Phenolic Compounds: Opportunities and Pharmacotherapeutic Perspectives

Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1254
Author(s):  
Naiara Naiana Dejani ◽  
Hatem A. Elshabrawy ◽  
Carlos da Silva Maia Bezerra Filho ◽  
Damião Pergentino de Sousa
Keyword(s):  
Phenolic Compounds ◽  
Mortality Rate ◽  
Immune Responses ◽  
Therapeutic Strategy ◽  
Kidney Diseases ◽  
Pharmacological Properties ◽  
The Novel ◽  
Dual Action ◽  
Natural Phenolic Compounds ◽  
Novel Coronavirus

In 2019, COVID-19 emerged as a severe respiratory disease that is caused by the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The disease has been associated with high mortality rate, especially in patients with comorbidities such as diabetes, cardiovascular and kidney diseases. This could be attributed to dysregulated immune responses and severe systemic inflammation in COVID-19 patients. The use of effective antiviral drugs against SARS-CoV-2 and modulation of the immune responses could be a potential therapeutic strategy for COVID-19. Studies have shown that natural phenolic compounds have several pharmacological properties, including anticoronavirus and immunomodulatory activities. Therefore, this review discusses the dual action of these natural products from the perspective of applicability at COVID-19.

scholarly journals Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology

Molecules ◽  
2020 ◽  
Vol 26 (1) ◽  
pp. 57
Author(s):  
Zhi-Ling Zhu ◽  
Xiao-Dan Qiu ◽  
Shuo Wu ◽  
Yi-Tong Liu ◽  
Ting Zhao ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Blocking Effect ◽  
Spike Protein ◽  
Binding Affinities ◽  
The Novel ◽  
Converting Enzyme ◽  
Primary Method ◽  
Angiotensin Converting Enzyme 2 ◽  
Novel Coronavirus ◽  
Effective Drugs

The novel coronavirus disease (2019-nCoV) has been affecting global health since the end of 2019, and there is no sign that the epidemic is abating. Targeting the interaction between the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor is a promising therapeutic strategy. In this study, surface plasmon resonance (SPR) was used as the primary method to screen a library of 960 compounds. A compound 02B05 (demethylzeylasteral, CAS number: 107316-88-1) that had high affinities for S-RBD and ACE2 was discovered, and binding affinities (KD, μM) of 02B05-ACE2 and 02B05-S-RBD were 1.736 and 1.039 μM, respectively. The results of a competition experiment showed that 02B05 could effectively block the binding of S-RBD to ACE2 protein. Furthermore, pseudovirus infection assay revealed that 02B05 could inhibit entry of SARS-CoV-2 pseudovirus into 293T cells to a certain extent at nontoxic concentration. The compoundobtained in this study serve as references for the design of drugs which have potential in the treatment of COVID-19 and can thus accelerate the process of developing effective drugs to treat SARS-CoV-2 infections.

scholarly journals Protective Immunity against COVID-19

2021 ◽  
Author(s):  
Anjali Priyadarshini ◽  
Archana Gupta ◽  
Manoj Kumar Yadav ◽  
Arpana Vibhuti ◽  
Ramendra Pati Pandey ◽  
...  
Keyword(s):  
United States ◽  
Immune Responses ◽  
Drug Administration ◽  
United States Of America ◽  
Protective Immunity ◽  
The United States ◽  
The Novel ◽  
Infectious Agents ◽  
Novel Coronavirus ◽  
Target Effects

Tuberculosis and Covid-19 infection measure two quite different diseases- TB is caused by a sort of bacterium whereas Covid-19 is caused by a virus. However, the BCG immunizing agent would possibly facilitate individuals build immune responses to things aside from TB, inflicting "off-target effects," In different words, in run format, individuals started learning positive in obtaining the immunizing agent that had nothing to try and do with TB, several studies showed however the BCG immunizing agent affects individuals with kind one although the precise mechanism for these off-target effects of the BCG immunizing agent is not clear, it's believed that the immunizing agent will cause a nonspecific boost of the reaction. There is presently no immunizing agent or treatments approved by the United States of America Food and Drug Administration for the novel coronavirus. BCG is usually innocuous with the most facet impact the event of inflammation at the positioning of injection. Supported by these observations BCG so emerges as a possible candidate for the development of innate and adjustive reactions which can be non-specifically taking care of mycobacterium and different infectious agents against that vaccine remains not on the market.

scholarly journals The first two months of COVID-19 pandemic in Bosnia and Herzegovina: Single-center experience

2020 ◽  
Author(s):  
Jurica Arapović ◽  
Siniša Skočibušić
Keyword(s):  
Mortality Rate ◽  
Severe Acute Respiratory Syndrome ◽  
Bosnia And Herzegovina ◽  
The Novel ◽  
Single Center ◽  
Single Centre ◽  
Single Center Experience ◽  
Single Centre Experience ◽  
Novel Coronavirus ◽  
The University

The novel coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still progressing and has been recorded in more than 210 countries and territories worldwide. In Bosnia and Herzegovina, the first cases of COVID-19 were detected on 5th of March 2020 in the entity of Republic of Srpska and 9th of March 2020 in the entity of Federation of Bosnia and Herzegovina. Up until the 16th of May 2020, more than 2,200 COVID-19 cases were recorded in both entities, with a mortality rate of 5.8% (131 out of 2231 cases). The aim of this ongoing study is to present the current epidemiological and sociodemographic parameters of 380 COVID-19 patients diagnosed at the University Clinical Hospital Mostar (UCH Mostar) during the first two months of the COVID-19 pandemic. Out of 380 patients, 60 (15.8%) of them required hospitalization. The mortality rate was 5% (19/380). The highest mortality rate of 15.2% (12/79) was recorded in the patients age ≥65 years. In addition to this single-centre experience of the ongoing COVID-19 pandemic, we discuss the epidemiological measures imposed in Bosnia and Herzegovina, with emphasis on the restrictive ones. The COVID-19 pandemic is still ongoing in Bosnia and Herzegovina.

scholarly journals Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers

2021 ◽  
Vol 9 (1) ◽  
pp. 159
Author(s):  
Mai M. Zafer ◽  
Hadir A. El-Mahallawy ◽  
Hossam M. Ashour
Keyword(s):  
Immune Responses ◽  
Multiorgan Failure ◽  
Serum Levels ◽  
Lung Damage ◽  
The Novel ◽  
Inflammatory Reactions ◽  
Dynamic Events ◽  
Cytokines And Chemokines ◽  
Plasma Leakage ◽  
Novel Coronavirus

The ongoing outbreak of the novel coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has taken a significant toll on people and countries all over the world. The pathogenesis of COVID-19 has not been completely elucidated yet. This includes the interplay between inflammation and coagulation which needs further investigation. The massive production of proinflammatory cytokines and chemokines results in the so-called cytokine storm, leading to plasma leakage, vascular hyperpermeability, and disseminated vascular coagulation. This is usually accompanied by multiorgan failure. The extensive changes in the serum levels of cytokines are thought to play a crucial role in the COVID-19 pathogenesis. Additionally, the viral load and host inflammation factors are believed to have a significant role in host damage, particularly lung damage, from SARS-CoV-2. Interestingly, patients exhibit quantitative and qualitative differences in their immune responses to the virus, which can impact the clinical manifestation and outcomes of COVID-19. There needs to be a better understanding of the dynamic events that involve immune responses, inflammatory reactions, and viral replication in the context of the COVID-19 infection. Here, we discuss the main aspects of COVID-19 pathogenesis while supporting the hypothesis that inflammatory immune responses are involved in the progression of the disease to a more critical and fatal phase. We also explore the similarities and differences between severe COVID-19 and sepsis. A deeper understanding of the COVID-19 clinical picture as it relates to better-known conditions such as sepsis can provide useful clues for the management, prevention, and therapy of the disease.

scholarly journals Delivery Routes for COVID-19 Vaccines

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 524
Author(s):  
Jang Hyun Park ◽  
Heung Kyu Lee
Keyword(s):  
Immune Responses ◽  
Viral Vector ◽  
Future Research ◽  
The Novel ◽  
Subunit Vaccines ◽  
Mucosal Vaccination ◽  
The Status ◽  
Delivery Routes ◽  
History Of ◽  
Novel Coronavirus

The novel coronavirus, SARS-CoV-2, which causes COVID-19, has resulted in a pandemic with millions of deaths. To eradicate SARS-CoV-2 and prevent further infections, many vaccine candidates have been developed. These vaccines include not only traditional subunit vaccines and attenuated or inactivated viral vaccines but also nucleic acid and viral vector vaccines. In contrast to the diversity in the platform technology, the delivery of vaccines is limited to intramuscular vaccination. Although intramuscular vaccination is safe and effective, mucosal vaccination could improve the local immune responses that block the spread of pathogens. However, a lack of understanding of mucosal immunity combined with the urgent need for a COVID-19 vaccine has resulted in only intramuscular vaccinations. In this review, we summarize the history of vaccines, current progress in COVID-19 vaccine technology, and the status of intranasal COVID-19 vaccines. Future research should determine the most effective route for vaccine delivery based on the platform and determine the mechanisms that underlie the efficacy of different delivery routes.

scholarly journals Histopathology and Pathogenesis of Coronavirus disease 2019 (COVID-19)

2020 ◽  
Vol 2 (3) ◽  
pp. 230-234
Author(s):  
Nikolaos Chrysanthakopoulos ◽  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Immune Responses ◽  
Good Prognosis ◽  
Multiple Organ ◽  
World Health ◽  
The Novel ◽  
Angiotensin Converting Enzyme 2 ◽  
Corona Virus ◽  
Novel Coronavirus ◽  
Health Organization

A severe pandemic of CoronaVirus disease 2019 (COVID-19), according to World Health Organization (WHO), appeared in China in December 2019, and spread rapidly. The majority of the patients had mild symptoms and good prognosis after recovery; however some patients developed severe inflammatory reaction and passed away from multiple organ complications. The novel coronavirus, Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) is a beta-coronavirus and is similar with the Severe Acute Respiratory Syndrome Corona Virus 1 (SARS-CoV-1) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). SARS-CoV-2 and -1 have the same host receptor, the angiotensin-converting enzyme 2 (ACE2). The pathogenesis of SARS-CoV-2 infection in humans remains unclear. The immune response is essential to control and reduce SARS-CoV-1 and -2 infections, however, irregular and exaggerated immune responses may lead to the immunopathology of the disease and the lung lesions. This article presents the immunological features of SARS-CoV-2 infection and its potential pathogenesis based on the recent observations of the International literature.

scholarly journals Statistical Analysis on the Impact of BCG Vaccination Policy of Different Economies on Coronavirus

2021 ◽  
Vol 9 (VII) ◽  
pp. 3038-3046
Author(s):  
Aniket Modi
Keyword(s):  
Statistical Analysis ◽  
Mortality Rate ◽  
Mortality Rates ◽  
Protective Effects ◽  
The Novel ◽  
Vaccination Policy ◽  
Bcg Vaccination ◽  
Novel Coronavirus ◽  
National Programs ◽  
The Impact

The novel coronavirus SARS-Cov-2 (Cov-2) results in COVID-19 infection which affects the respiratory tract of the human body, so we investigated whether the BCG vaccine offers some protection against CoV-2 infection. Herein we examine whether the national programs that use BCG vaccination to reduce tuberculosis infections might be responsible for different incident and mortality rates which is observed in Covid-19 among various countries. There is some mechanistic evidence that shows the BCG vaccination can have some protective effects against the Covid-19 virus. Through our observation, we see that countries that still follow BCG vaccination policy have a significantly lower mortality rate than those countries that have discontinued this policy or never had one.

scholarly journals The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines

2021 ◽  
Vol 12 ◽  
Author(s):  
Renee W. Y. Chan ◽  
Shaojun Liu ◽  
Jonathan Y. Cheung ◽  
Joseph G. S. Tsun ◽  
Kate C. Chan ◽  
...  
Keyword(s):  
Immune Responses ◽  
Immunological Response ◽  
Similar Response ◽  
The Novel ◽  
Epithelial Lining Fluid ◽  
Specific Immunoglobulin ◽  
Additional Protection ◽  
Specific Igg ◽  
Novel Coronavirus ◽  
Systemic Responses

BackgroundAlthough the serological antibody responses induced by SARS-CoV-2 vaccines are well characterized, little is known about their ability to elicit mucosal immunity.ObjectivesThis study aims to examine and compare the mucosal and systemic responses of recipients of two different vaccination platforms: mRNA (Comirnaty) and inactivated virus (CoronaVac).MethodsSerial blood and nasal epithelial lining fluid (NELF) samples were collected from the recipients of either Comirnaty or CoronaVac. The plasma and NELF immunoglobulins A and G (IgA and IgG) specific to SARS-CoV-2 S1 protein (S1) and their neutralization effects were quantified.ResultsComirnaty induced nasal S1-specific immunoglobulin responses, which were evident as early as 14 ± 2 days after the first dose. In 64% of the subjects, the neutralizing effects of NELF persisted for at least 50 days. Moreover, 85% of Comirnaty recipients exhibited S1-specific IgA and IgG responses in plasma by 14 ± 2 days after the first dose. By 7 ± 2 days after the booster, all plasma samples possessed S1-specific IgA and IgG responses and were neutralizing. The induction of S1-specific plasma antibodies by CoronaVac was IgG dominant, and 83% of the subjects possessed S1-specific IgG by 7 ± 2 days after the booster, with neutralizing effects.ConclusionComirnaty induces S1-specific IgA and IgG responses with neutralizing activity in the nasal mucosa; a similar response is not seen with CoronaVac.Clinical ImplicationThe presence of a nasal response with mRNA vaccine may provide additional protection compared with inactivated virus vaccine. However, whether such widespread immunological response may produce inadvertent adverse effects in other tissues warrants further investigation.

scholarly journals MantisCOVID: Rapid X-Ray Chest Radiograph and Mortality Rate Evaluation With Artificial Intelligence For COVID-19

2020 ◽  
Author(s):  
Yağmur Yaşar ◽  
Berat Tuna Karli ◽  
Cem Çöteli ◽  
Mert Burkay Çöteli
Keyword(s):  
Artificial Intelligence ◽  
Mortality Rate ◽  
Chest Radiograph ◽  
Well Being ◽  
Health Economy ◽  
Diagnostic Tools ◽  
Healthy Population ◽  
The Novel ◽  
X Ray ◽  
Novel Coronavirus

AbstractThe novel coronavirus pandemic has negative impacts over the health, economy and well-being of the global population. This negative effect is growing with the high spreading rate of the virus. The most critical step to prevent the spreading of the virus is pre-screening and early diagnosis of the individuals. This results in quaranteeing the patients not to effect the healthy population. COVID-19 is the name of the disease caused by the novel coronavirus. It has a high infection rate and it is urgent to diagnose many patients as we can to prevent the spread of the virus at the early stage. Rapid diagnostic tools development is urgent to save lives. MantisCOVID is a cloud-based pre-diagnosis tool to be accessed from the internet. This tool delivers a rapid screening test by analyzing the X-ray Chest Radiograph scans via Artificial Intelligence (AI) and it also evaluates the mortality rate of patients with the synthesis of the patient’s history with the machine learning methods. This study reveals the methods used over the platform and evaluation of the algorithms via open datasets.

scholarly journals Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges

Life Sciences ◽  
2020 ◽  
Vol 257 ◽  
pp. 118058 ◽  
Author(s):  
Mahsa Hajivalili ◽  
Maryam Hosseini ◽  
Mostafa Haji-Fatahaliha
Keyword(s):  
Immune Responses ◽  
The Novel ◽  
Novel Coronavirus
Sign in / Sign up

Export Citation Format

Share Document